bioAffinity Technologies (NASDAQ: BIAF) has announced that the Japan Patent Office (JPO) has issued a notice of allowance (NOA) indicating its intention to grant a patent covering bioAffinity’s non-invasive lung cancer...
bioAffinity Technologies (NASDAQ: BIAF; BIAFW) has initiated a planned large-scale, longitudinal clinical study for CyPath Lung, its noninvasive diagnostic test for the detection of early-stage lung cancer. The 2,000...
bioAffinity Technologies (NASDAQ:BIAF) is rolling out CyPath Lung, an accurate, non-invasive and cost-effective test for the early detection of lung cancer, in the U.S. Southwest before a staged nationwide launch.